New schizophrenia drug shows promise in safety extension trial

NCT ID NCT05741528

Completed Disease control Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at the safety of a new drug called SEP-363856 for people with schizophrenia who switched from their usual antipsychotic medication. 75 participants who completed a prior study were followed for up to 25 weeks. The main goal was to track any side effects or serious health issues. This is a disease control study because schizophrenia requires ongoing management.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Research Site

Anaheim, California, 92805, United States
Research Site

Bellflower, California, 90706, United States
Research Site

Garden Grove, California, 92845, United States
Research Site

Lemon Grove, California, 91945, United States
Research Site

Santee, California, 92071, United States
Research Site

Torrance, California, 90502, United States
Research Site

Hollywood, Florida, 33021, United States
Research Site

Miami, Florida, 33122, United States
Research Site

Atlanta, Georgia, 30318, United States
Research Site

Atlanta, Georgia, 30331, United States
Research Site

Chicago, Illinois, 60640, United States
Research Site

Gaithersburg, Maryland, 20877, United States
Research Site

Berlin, New Jersey, 08009, United States
Research Site

Charlotte, North Carolina, 28211, United States
Research Site

Hickory, North Carolina, 28601, United States
Research Site

Richardson, Texas, 75080, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.